Phase II, Randomised, Double-Blind, Two-Arm, Parallel Study of Vandetanib (ZACTIMA, ZD6474) Plus Gemcitabine (Gemzar) or Gemcitabine Plus Placebo as First Line Treatment of Advanced (Stage IIIB or IV) Non Small Cell Lung Cancer (NSCLC) Elderly Patients.

Trial Profile

Phase II, Randomised, Double-Blind, Two-Arm, Parallel Study of Vandetanib (ZACTIMA, ZD6474) Plus Gemcitabine (Gemzar) or Gemcitabine Plus Placebo as First Line Treatment of Advanced (Stage IIIB or IV) Non Small Cell Lung Cancer (NSCLC) Elderly Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2016

At a glance

  • Drugs Vandetanib (Primary) ; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ZELIG
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 May 2014 Results published in the Journal of Thoracic Oncology.
    • 02 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
    • 27 Mar 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top